Myriad Genetics (MYGN) Misses Q1 EPS by 2c ; Offers Guidance
Tweet
Share
E-mail
Get Alerts MYGN Hot Sheet
Price: $2.97 -7.76%
Revenue Growth %: -4.9%
Financial Fact:
Total revenue: 177.5M
Today's EPS Names:
PMCB, PLCE, DOMO, More
Revenue Growth %: -4.9%
Financial Fact:
Total revenue: 177.5M
Today's EPS Names:
PMCB, PLCE, DOMO, More
Join SI Premium – FREE
Myriad Genetics (NASDAQ: MYGN) reported Q1 EPS of ($0.09), $0.02 worse than the analyst estimate of ($0.07). Revenue for the quarter came in at $200.4 million versus the consensus estimate of $202.39 million.
GUIDANCE:
Myriad Genetics sees FY2026 revenue of $80.6-0.88 billion, versus the consensus of $1.53 billion.
For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Piper Sandler Double Downgrades Myriad Genetics (MYGN) to Underweight, 'Major Strategic Action Likely Needed'
- Medtronic (MDT) Tops Q1 EPS by 6c, Beats on Revenue; Offers FY27 EPS Guidance
- C3 AI (AI) call put ratio 1.6 calls to 1 put into quarter results
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
